Skip to main content

Advertisement

SpringerLink
Log in

Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

  • Guidelines
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

An Erratum to this article was published on 30 August 2017

This article has been updated

Abstract

Purpose & Methods

Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms.

Results & Conclusion

The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Change history

  • 30 August 2017

    An erratum to this article has been published.

References

  1. Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol. 2001;12(Suppl 2):S51–61.

    Article  PubMed  Google Scholar 

  2. Olsen JO, Pozderac RV, Hinkle G, Hill T, O’Dorisio TM, Schirmer WJ, et al. Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan). Semin Nucl Med. 1995;25:251–61.

    Article  CAS  PubMed  Google Scholar 

  3. Briganti V, Sestini R, Orlando C, Bernini G, La Cava G, Tamburini A, et al. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastomatumors. Clin Cancer Res. 1997;3:2385–91.

    CAS  PubMed  Google Scholar 

  4. Chiti A, Briganti V, Fanti S, Monetti N, Masi R, Bombardieri E. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours. Q J Nucl Med. 2000;44:42–9.

    CAS  PubMed  Google Scholar 

  5. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours. Eur J Nucl Med. 1998;25:1396–403.

    Article  CAS  PubMed  Google Scholar 

  6. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.

    Article  CAS  PubMed  Google Scholar 

  7. Seregni E, Chiti A, Bombardieri E. Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med. 1998;25:639–58.

    Article  CAS  PubMed  Google Scholar 

  8. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management. J Nucl Med. 1995;36:542–9.

    CAS  PubMed  Google Scholar 

  9. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatictumors. J Nucl Med. 1997;38:853–8.

    CAS  PubMed  Google Scholar 

  10. Kowalski J, Henze M, Schuhmacher J, Maecke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1 Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.

    Article  PubMed  Google Scholar 

  11. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003;30:781–93.

    Article  CAS  PubMed  Google Scholar 

  12. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.

    Article  CAS  PubMed  Google Scholar 

  13. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28:1751–7.

    Article  CAS  PubMed  Google Scholar 

  14. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.

    Article  CAS  PubMed  Google Scholar 

  15. Campana D, Ambrosini V, Pezzilli R, Fanti S, Labate AM, Santini D, et al. Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med. 2010;51:353–9.

    Article  PubMed  Google Scholar 

  16. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.

    Article  CAS  PubMed  Google Scholar 

  17. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389–427.

    Article  CAS  PubMed  Google Scholar 

  18. Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: (68)Ga-DOTA (0),Tyr (3)-octreotide versus (68)Ga-DOTA (0)-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40:364–72.

    Article  CAS  PubMed  Google Scholar 

  19. Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med. 2012;53:1207–15.

    Article  CAS  PubMed  Google Scholar 

  20. Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjaer A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology. 2008;87:223–32.

    Article  CAS  PubMed  Google Scholar 

  21. Wang X, Fani M, Schulz S, Rivier J, Reubi JC, Maecke HR. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy. Eur J Nucl Med Mol Imaging. 2012;39:1876–85.

    Article  CAS  PubMed  Google Scholar 

  22. Virgolini I, Innsbruck Team. Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur J Nucl Med Mol Imaging. 2015;42:1949–54.

    Article  PubMed  Google Scholar 

  23. Kauhanen S, Seppänen M, Ovaska J, Minn H, Bergman J, Korsoff P, et al. The clinical value of [18F]fluoro-dihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors. Endocr Relat Cancer. 2009;16:255–65.

    Article  CAS  PubMed  Google Scholar 

  24. Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:1265–72.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Gotthardt M, Béhé MP, Beuter D, Battmann A, Bauhofer A, Schurrat T, et al. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2006;33:1273–9.

    Article  PubMed  Google Scholar 

  26. Gotthardt M, Béhé MP, Grass J, Bauhofer A, Rinke A, Schipper ML, et al. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer. 2006;13:1203–11.

    Article  PubMed  Google Scholar 

  27. Pawlak D, Rangger C, KolencPeitl P, Garnuszek P, Maurin M, Ihli L, et al. From preclinical development to clinical application: kit formulation for radiolabelling the minigastrin analogue CP04 with in-111 for a first-in-human clinical trial. Eur J Pharm Sci. 2016;85:1–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85.

    Article  CAS  PubMed  Google Scholar 

  29. Woltering EA, Bergsland EK, Beyer DT. Neuroendocrine Tumors of the Stomach. American Joint Committee on Cancer 2017. In: Amin MB editor. AJCC Cancer Staging Manual. Eighth Edition. Springer 2017: 351–359. doi: 10.1007/978-3-319-40618-3_30.

  30. Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, et al. Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging. 2016;43:1585–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Ambrosini V, Marzola MC, Rubello D, Fanti S. (68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:46–8.

    Article  PubMed  Google Scholar 

  32. Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:49–57.

    Article  CAS  PubMed  Google Scholar 

  33. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.

    Article  PubMed  Google Scholar 

  34. Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2008;35:1431–8.

    Article  CAS  PubMed  Google Scholar 

  35. Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62:667–71.

    Article  CAS  PubMed  Google Scholar 

  36. Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009;50:1927–32.

    Article  PubMed  Google Scholar 

  37. Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V, et al. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009;30:281–6.

    Article  PubMed  Google Scholar 

  38. Schartinger VH, Dudás J, Decristoforo C, Url C, Schnabl J, Göbel G, et al. 68Ga-DOTA0-Tyr3-octreotide positron emission tomography in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1365–72.

    Article  PubMed  Google Scholar 

  39. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.

    CAS  PubMed  Google Scholar 

  40. Nanni C, Fantini L, Nicolini S, Fanti S. Non FDG PET. Clin Radiol. 2010;65:536–48.

    Article  CAS  PubMed  Google Scholar 

  41. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468–81.

    Article  PubMed  Google Scholar 

  42. Kauhanen S, Seppänen M, Minn H, Gullichsen R, Salonen A, Alanen K, et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007;92:1237–44.

    Article  CAS  PubMed  Google Scholar 

  43. Traub-Weidinger T, Putzer D, von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42:1995–2001.

    Article  CAS  PubMed  Google Scholar 

  44. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67–77.

    Article  CAS  PubMed  Google Scholar 

  45. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50:1214–21.

    Article  PubMed  Google Scholar 

  46. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P, et al. (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2010;37:722–7.

    Article  PubMed  Google Scholar 

  47. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, et al. Ga-66 labeledsomatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol. 2002;29:147–57.

    Article  CAS  PubMed  Google Scholar 

  48. Gabriel M, Oberauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med. 2009;50:1427–34.

    Article  CAS  PubMed  Google Scholar 

  49. Öksüz MÖ, Winter L, Pfannenberg C, Reischl G, Müssig K, Bares R, Dittmann H. Peptide receptor radionuclide therapy of neuroendocrine tumorswith(90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of(68)Ga-DOTATOC? Diagn Interv Imaging. 2014;95:289–300.

    Article  PubMed  Google Scholar 

  50. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedureguidelinesfor PET/CT tumourimagingwith 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10.

  51. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sörensen J, Bergström M, Långström B. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol. 2010;37:265–75.

    Article  CAS  PubMed  Google Scholar 

  52. Ezziddin S, Lohmar J, Yong-Hing CJ, Sabet A, Ahmadzadehfar H, Kukuk G, et al. Does the pretherapeutictumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate? Clin Nucl Med. 2012;37:e141–7.

    Article  PubMed  Google Scholar 

  53. Machado JS, Beykan S, Herrmann K, Lassmann M. Recommendedadministeredactivitiesfor (68)Ga-labelled peptides in paediatricnuclearmedicine. Eur J Nucl Med Mol Imaging. 2016;43:2036–9.

    Article  CAS  PubMed  Google Scholar 

  54. Hartmann H, Zöphel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48:201–7.

    CAS  PubMed  Google Scholar 

  55. Pettinato C, Sarnelli A, Di Donna M, Civollani S, Nanni C, Montini G, et al. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2008;35:72–9.

    Article  CAS  PubMed  Google Scholar 

  56. Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013;54:855–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Koopmans KP, Groot JW, Plukker JT, de Vries EG, Kema IP, Sluiter WJ, et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524–31.

    Article  CAS  PubMed  Google Scholar 

  58. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergström M, Långström B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19:311–24.

    Article  CAS  PubMed  Google Scholar 

  59. Timmers HJ, Hadi M, Carrasquillo JA, Chen CC, Martiniova L, Whatley M, et al. The effects of carbidopa on uptake of 6-18F-Fluoro-L-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma. J Nucl Med. 2007;48:1599–606.

    Article  CAS  PubMed  Google Scholar 

  60. Ribeiro MJ, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, et al. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-L-DOPA. J Nucl Med. 2005;46:560–6.

    PubMed  Google Scholar 

  61. Kauhanen S, Seppänen M, Nuutila P. Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [(18)F]-dihydroxy-phenyl-alanine positron emission tomography. J Clin Oncol. 2008;26:5307–8. author reply 5308–9

    Article  PubMed  Google Scholar 

  62. Imperiale A, Bahougne T, Goichot B, Bachellier P, Taïeb D, Namer IJ. Dynamic 18F-FDOPA PET findings after carbidopa premedication in 2 adult patients with insulinoma-related hyperinsulinemichypoglycemia. Clin Nucl Med. 2015;40:682–4.

    Article  PubMed  Google Scholar 

  63. Imperiale A, Sebag F, Vix M, Castinetti F, Kessler L, Moreau F, et al. 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur J Nucl Med Mol Imaging. 2015;42:409–18.

    Article  CAS  PubMed  Google Scholar 

  64. Koopmans KP, Brouwers AH, De Hooge MN, Van der Horst-Schrivers AN, Kema IP, Wolffenbuttel BH, et al. Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid. J Nucl Med. 2005;46:1240–3.

    PubMed  Google Scholar 

  65. Nataf V, Balard M, de Beco V, Kerrou K, Gutman F, Grahek D, et al. Safety of 18F-DOPA injection for PET of carcinoid tumor. J Nucl Med. 2006;47:1732. author reply 1732

    PubMed  Google Scholar 

  66. Virgolini I, Gabriel M, Kroiss A, von Guggenberg E, Prommegger R, Warwitz B, et al. Current knowledge on the sensitivity of the(68)Ga-Somatostatinreceptor positron emission tomography and the SUVmaxreference range for management of pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2016;43:2072–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271–7.

    Article  PubMed  Google Scholar 

  68. Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.

    Article  CAS  PubMed  Google Scholar 

  69. Grassetto G, Massaro A, Cittadin S, Padoan A, Manara R, D’Avella D, et al. Kinetic of 18F-DOPA in basal ganglia of non-human primate. Eur J Nucl Med Mol Imaging. 2009;(Suppl 2):36, S469–S469.

  70. Lopci E, D’Ambrosio D, Nanni C, Chiti A, Pession A, Marengo M, Fanti S. Feasibility of carbidopa premedication in pediatricpatients:a pilot study. Cancer Biother Radiopharm. 2012;27:729–33.

    Article  CAS  PubMed  Google Scholar 

  71. Decristoforo C, Pickett RD, Verbruggen A. Feasibility and availability of 68Ga-labelled peptides. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S31–40.

    Article  PubMed  Google Scholar 

  72. Velikyan I. 68Ga-based radiopharmaceuticals: production and application relationship. Molecules. 2015;20:12913–43.

    Article  CAS  PubMed  Google Scholar 

  73. Balan KK. Visualization of the gall bladder on F-18 FDOPA PET imaging: a potential pitfall. Clin Nucl Med. 2005;30:23–4.

    Article  PubMed  Google Scholar 

  74. Tessonnier L, Sebag F, Ghander C, De Micco C, Reynaud R, Palazzo FF, et al. Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemichypoglycemia. J Clin Endocrinol Metab. 2010;95:303–7.

    Article  CAS  PubMed  Google Scholar 

  75. Koopmans KP, de Vries EG, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728–34.

    Article  CAS  PubMed  Google Scholar 

  76. Treglia G, Rufini V, Salvatori M, Giordano A, Giovanella L. PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging. 2012;2012:324686.

    PubMed  PubMed Central  Google Scholar 

  77. Treglia G, Cocciolillo F, de Waure C, Di Nardo F, Gualano MR, Castaldi P, et al. Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. Eur J Nucl Med Mol Imaging. 2012;39:1144–53.

    Article  PubMed  Google Scholar 

  78. Blake MA, Singh A, Setty BN, Slattery J, Kalra M, Maher MM, et al. Pearls and pitfalls in interpretation of abdominal and pelvic PET-CT. Radiographics. 2006;26:1335–53.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, Turkey

    Murat Fani Bozkurt

  2. Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria

    Irene Virgolini & Clemens Decristoforo

  3. Department of Nuclear Medicine, Comenius University and St. Elisabeth Oncology Institute, Bratislava, Slovakia

    Sona Balogova

  4. Department of Nuclear Medicine, Tenon Hospital AP-HP & Université Pierre et Marie Curie, Paris, France

    Sona Balogova

  5. PET-CT Center, Department of Nuclear Medicine & Endocrinology, St. Vincent’s Hospital, Linz, Austria

    Mohsen Beheshti

  6. Department of Nuclear Medicine, Paracelsus Medical University, Salzburg, Austria

    Mohsen Beheshti

  7. Department of Nuclear Medicine, PET Center and Medical Physics and Radiology, Santa Maria della Misericordia Hospital, Rovigo, Italy

    Domenico Rubello

  8. Department of Experimental, Diagnostic and Specialty Medicine-DIMES, University of Bologna, Bologna, Italy

    Valentina Ambrosini & Stefano Fanti

  9. Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, National University Hospital & University of Copenhagen, Copenhagen, Denmark

    Andreas Kjaer

  10. Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, San Pedro Hospital and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, Spain

    Roberto Delgado-Bolton

  11. Nuclear Medicine, Medical University of Warsaw, Warsaw, Poland

    Jolanta Kunikowska

  12. Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK

    Wim J. G. Oyen

  13. Nuclear Medicine Department, Humanitas University, Rozzano, MI, Italy

    Arturo Chiti

  14. Nuclear Medicine, University of Lyon, Lyon, France

    Francesco Giammarile

Authors
  1. Murat Fani Bozkurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irene Virgolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sona Balogova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohsen Beheshti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Domenico Rubello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Clemens Decristoforo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Valentina Ambrosini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andreas Kjaer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Roberto Delgado-Bolton
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jolanta Kunikowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wim J. G. Oyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Arturo Chiti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Francesco Giammarile
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Stefano Fanti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Murat Fani Bozkurt or Roberto Delgado-Bolton.

Ethics declarations

Funding

None.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

An erratum to this article is available at https://doi.org/10.1007/s00259-017-3807-0.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bozkurt, M.F., Virgolini, I., Balogova, S. et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA. Eur J Nucl Med Mol Imaging 44, 1588–1601 (2017). https://doi.org/10.1007/s00259-017-3728-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-017-3728-y

Keywords

Search

Navigation